Manuel Modiano MD

Breast Cancer, Gastrointestinal Cancer, Thoracic Cancer

Arizona Blood and Cancer Specialists. Medical Director, ACRC/Arizona Clinical Research Center. Tucson, AZ

3945 E Paradise Falls DrSte 105Tucson, AZ 85712
Phone+1 520-689-7030
Fax+1 520-395-9796

Dr. Modiano is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Modiano's full profile Already have an account?

Education & Training

University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1987 - 1989
Aurora Health CareResidency, Internal Medicine, 1984 - 1987
Universidad Nacional Autonoma de MexicoClass of 1981

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

AZ State Medical License 1987 - 2027
WI State Medical License 1985 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification iKnowMed™ EHR, US Oncology, 2012, 2014-2017

Clinical Trials

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
COMPLETED
PHASE1, PHASE2
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
COMPLETED
PHASE3
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapy.
Manuel Modiano, Shanta Chawla, Jeffrey L Vacirca, Kenneth Crist, Howard Franklin
The Oncologist. 2025-12-27
11 citations
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
Darren Pan, Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder
Cancer Medicine. 2022-01-01
16 citations
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in ope...
Daniel P. Petrylak, Nicholas J. Vogelzang, Kamal Chatta, Mark D. Fleming, David Smith
The Prostate. 2020-01-01